A Phase 3 interventional study of Arformoterol and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Sumitomo Pharma America, Inc.. Completed at 73 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-11-11.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 21st largest by enrollment, is one of 2 that started in 2009, is one of 40 in phase 3, and was the 26th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 841 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 89 interventional studies. Of the 80 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 24 finished, 15 (63%) have results posted.
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., this one is the 2nd largest by enrollment, is one of 2 that started in 2009, is one of 11 in phase 3, and was the 13th registered.
Sumitomo Pharma Co., Ltd.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2001.
1 of the studies testing formoterol in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 24 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. Study participation will consist of a total of 6 visits over approximately 1 year.
This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group, outpatient, safety study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. The administration of arformoterol in subjects with moderate to severe COPD will not result in a meaningfully greater incidence of respiratory death and COPD exacerbation -related hospitalizations compared to placebo (nebulized saline and non-long-acting beta2-agonist [LABA] COPD standard of care treatments). This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
Drug: Arformoterol
Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
Drug: Placebo
Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
Also known as: Brovana
Placebo inhalation solution, twice daily (BID) for a duration of one year.
Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).
COPD exacerbation: an increase in COPD symptoms that necessitated any change in baseline medication (bronchodilators,anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc.).Hospitalization: any inpatient admission or any emergency department visit \> 24 hours in duration. Hospice was considered hospitalization.COPD exacerbation related hospitalization: hospitalization that was due to 1) COPD exacerbation or 2) a COPD exacerbation preceded, or occurred concomitantly with the onset of, the event for which the subject was hospitalized.Respiratory-related death: For each death the Primary Investigator designated a 'probable cause', which was the primary condition that precipitated the terminal events that were the immediate cause of death. If a probable cause could not be ascertained, the cause of death was considered 'UNKNOWN'. Cause other than 'UNKNOWN' was categorized as either respiratory or non-respiratory. Deaths of 'UNKNOWN' cause were counted as primary events.
Time frame: 0-12 months
The Incidence of Protocol Defined COPD Exacerbations.
A protocol-defined exacerbation of COPD was defined as an increase in respiratory symptoms (classically, increased shortness of breath, increased sputum production, and/or increased sputum purulence) that necessitates any change in baseline medication other than bronchodilators (e.g., anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc) or causes the subject to require additional medical attention (i.e., emergency room visit or hospitalization).
Time frame: 0-12 months
The Incidence of All Cause Mortality
Survival status at the end of the study will be determined for each subject. The proportion of subjects dead and the annual event rate will be summarized by treatment.
Time frame: 0-12 months
The Incidence of Treatment Emergent AEs
TEAEs were defined as: 1) adverse events that occurred on or after the date of first dose of study medication, 2) adverse events with a missing start date and a stop date on or after the date of first does of study medication, or 3) adverse events with both a missing start and stop date. The frequency and percentage of subjects with TEAEs were summarized. At each level of summarization, a subject was counted only once for each AE he/she experienced within that level. The percentage of subjects having had at least 1 AE at each level was calculated.
Time frame: 0-12 months
SGRQ: Mean Change From Baseline in Total Score
The SGRQ assessed health status and consisted of 3 component scores (Symptoms, Activity, and Impacts) as well as a total score. Items were scored in accordance with the developer's guidelines. Scores were expressed as a percentage of overall impairment, where 100 represented worst possible health status and 0 indicated best possible health status. The SGRQ was assessed pre-dose at baseline, months 3, 6 and 12 or the end of study (EOS). Visit 2 was defined as baseline. A change from baseline in the Total Score of ≥ 4 units is considered the minimal clinically important difference (MCID) for SGRQ.
Time frame: Baseline and on treatment at months 3, 6 and 12 (or early termination)
FEV1: Mean Change From Baseline
FEV1 was measured at Visit 1 (screening), pre- and post-albuterol administration for reversibility testing, pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FEV1 from at least 3 acceptable maneuvers was recorded. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last FEV1 value obtained prior to first treatment was used for baseline.
Time frame: Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)
Percent Predicted FEV1: Mean Change From Baseline
Percent predicted FEV1: measured FEV1 as a percent of the "predicted values" for the patients of similar characteristics (height, age, sex, and sometimes race and weight). Best FEV1 percent predicted was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS, as described for FEV1.
Time frame: Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)
Forced Vital Capacity (FVC): Mean Change From Baseline
Forced Vital capacity: the volume of air that can forcibly be blown out after full inspiration. Best FVC was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FVC from at least 3 acceptable maneuvers was recorded.
Time frame: Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)
Inspiratory Capacity (IC): Mean Change From Baseline
IC: the total amount of air that can be drawn into the lungs after normal expiration. IC was measured pre- and post-albuterol administration at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. IC maneuvers were done in triplicate. The mean of all recorded IC values was used for each subject at each time point. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last IC value obtained prior to first treatment dose was used for baseline.
Time frame: Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)
| Milestone | Placebo Twice Daily | Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| Started | 421 | 420 |
| Completed | 211 | 255 |
| Not completed | 210 | 165 |
| Withdrew: Adverse event | 53 | 55 |
| Withdrew: Lack of efficacy | 7 | 4 |
| Withdrew: Lost to follow-up | 19 | 15 |
| Withdrew: Physician decision | 8 | 2 |
| Withdrew: Protocol violation | 2 | 5 |
| Withdrew: Withdrawal by subject | 116 | 80 |
| Withdrew: Site ceasing operation | 2 | 2 |
| Withdrew: Medical monitor decision | 1 | 0 |
| Withdrew: Noncompliance | 1 | 1 |
| Withdrew: Randomized in error | 1 | 1 |
COPD exacerbation: an increase in COPD symptoms that necessitated any change in baseline medication (bronchodilators,anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc.).Hospitalization: any inpatient admission or any emergency department visit \> 24 hours in duration. Hospice was considered hospitalization.COPD exacerbation related hospitalization: hospitalization that was due to 1) COPD exacerbation or 2) a COPD exacerbation preceded, or occurred concomitantly with the onset of, the event for which the subject was hospitalized.Respiratory-related death: For each death the Primary Investigator designated a 'probable cause', which was the primary condition that precipitated the terminal events that were the immediate cause of death. If a probable cause could not be ascertained, the cause of death was considered 'UNKNOWN'. Cause other than 'UNKNOWN' was categorized as either respiratory or non-respiratory. Deaths of 'UNKNOWN' cause were counted as primary events.
| Days | Experimental: Arformoterol 15 Mcg Twice Daily | Placebo |
|---|---|---|
| Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First). | 155.0 ± 91.2 | 171.7 ± 98.7 |
A protocol-defined exacerbation of COPD was defined as an increase in respiratory symptoms (classically, increased shortness of breath, increased sputum production, and/or increased sputum purulence) that necessitates any change in baseline medication other than bronchodilators (e.g., anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc) or causes the subject to require additional medical attention (i.e., emergency room visit or hospitalization).
| participants | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| Overall | 132 | 122 |
| 1 COPD event | 72 | 71 |
| 2 COPD events | 34 | 29 |
| 3 or more COPD events | 26 | 22 |
Survival status at the end of the study will be determined for each subject. The proportion of subjects dead and the annual event rate will be summarized by treatment.
| participants | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| The Incidence of All Cause Mortality | 10 | 12 |
TEAEs were defined as: 1) adverse events that occurred on or after the date of first dose of study medication, 2) adverse events with a missing start date and a stop date on or after the date of first does of study medication, or 3) adverse events with both a missing start and stop date. The frequency and percentage of subjects with TEAEs were summarized. At each level of summarization, a subject was counted only once for each AE he/she experienced within that level. The percentage of subjects having had at least 1 AE at each level was calculated.
| participants | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| The Incidence of Treatment Emergent AEs | 287 | 306 |
The SGRQ assessed health status and consisted of 3 component scores (Symptoms, Activity, and Impacts) as well as a total score. Items were scored in accordance with the developer's guidelines. Scores were expressed as a percentage of overall impairment, where 100 represented worst possible health status and 0 indicated best possible health status. The SGRQ was assessed pre-dose at baseline, months 3, 6 and 12 or the end of study (EOS). Visit 2 was defined as baseline. A change from baseline in the Total Score of ≥ 4 units is considered the minimal clinically important difference (MCID) for SGRQ.
| Score | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| Month 3 (n=276,308) | -1.544 ± 0.609 | -3.876 ± 0.575 |
| Month 6 (n=233,287) | -1.855 ± 0.746 | -4.054 ± 0.679 |
| Month 12 (n=199,236) | -2.673 ± 0.800 | -4.796 ± 0.735 |
| EOS (n=375,379) | -0.587 ± 0.616 | -3.231 ± 0.613 |
FEV1 was measured at Visit 1 (screening), pre- and post-albuterol administration for reversibility testing, pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FEV1 from at least 3 acceptable maneuvers was recorded. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last FEV1 value obtained prior to first treatment was used for baseline.
| Liter | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| Month 3 (n=289,331) | 0.027 ± 0.018 | 0.093 ± 0.016 |
| Month 6 (n=248,300) | 0.036 ± 0.023 | 0.090 ± 0.021 |
| Month 9 (n=223,268) | 0.048 ± 0.019 | 0.092 ± 0.018 |
| Month 12 (n=206,253) | 0.020 ± 0.020 | 0.059 ± 0.018 |
| EOS (n=380,391) | 0.047 ± 0.016 | 0.072 ± 0.016 |
Percent predicted FEV1: measured FEV1 as a percent of the "predicted values" for the patients of similar characteristics (height, age, sex, and sometimes race and weight). Best FEV1 percent predicted was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS, as described for FEV1.
| Liter | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| Month 3 (n=289,331) | 1.410 ± 0.533 | 3.480 ± 0.498 |
| Month 6 (n=248,300) | 1.768 ± 0.648 | 3.460 ± 0.594 |
| Month 9 (n=223,268) | 2.606 ± 0.626 | 3.651 ± 0.576 |
| Month 12 (n=206,252) | 1.678 ± 0.642 | 2.662 ± 0.586 |
| EOS (n=380,391) | 2.156 ± 0.493 | 2.936 ± 0.486 |
Forced Vital capacity: the volume of air that can forcibly be blown out after full inspiration. Best FVC was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FVC from at least 3 acceptable maneuvers was recorded.
| Liter | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| Month 3 (n=289,331) | 0.039 ± 0.024 | 0.139 ± 0.022 |
| Month 6 (n=248,300) | 0.056 ± 0.031 | 0.120 ± 0.028 |
| Month 9 (n=223,268) | 0.049 ± 0.029 | 0.139 ± 0.027 |
| Month 12 (n=206,253) | 0.040 ± 0.029 | 0.088 ± 0.027 |
| EOS (n=380,391) | 0.056 ± 0.022 | 0.102 ± 0.022 |
IC: the total amount of air that can be drawn into the lungs after normal expiration. IC was measured pre- and post-albuterol administration at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. IC maneuvers were done in triplicate. The mean of all recorded IC values was used for each subject at each time point. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last IC value obtained prior to first treatment dose was used for baseline.
| Liter | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| Month 3 (n=284,320) | 0.030 ± 0.023 | 0.054 ± 0.021 |
| Month 6 (n=243,298) | -0.011 ± 0.026 | 0.067 ± 0.024 |
| Month 9 (n=218,258) | 0.046 ± 0.029 | 0.096 ± 0.027 |
| Month 12 (n=199,246) | 0.004 ± 0.029 | 0.035 ± 0.027 |
| EOS (n=374,384) | 0.031 ± 0.022 | 0.058 ± 0.021 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Comparator: Placebo Twice Daily | — | 95/421 (22.6%) | 180/421 (42.8%) |
| Experimental: Arformoterol 15 Mcg Twice Daily | — | 86/420 (20.5%) | 174/420 (41.4%) |
| Event | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 55/421 | 35/420 |
| PneumoniaInfections and infestations | 14/421 | 12/420 |
| BronchitisInfections and infestations | 9/421 | 3/420 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 4/421 | 1/420 |
| Angina pectorisCardiac disorders | 1/421 | 3/420 |
| Atrial fibrillationCardiac disorders | 2/421 | 3/420 |
| Coronary artery diseaseCardiac disorders | 0/421 | 3/420 |
| Non-cardiac chest painGeneral disorders | 1/421 | 3/420 |
| SepsisInfections and infestations | 0/421 | 3/420 |
| Cardiac failure congestiveCardiac disorders | 3/421 | 2/420 |
| Event | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 83/421 | 75/420 |
| BronchitisInfections and infestations | 28/421 | 43/420 |
| NasopharyngitisInfections and infestations | 33/421 | 38/420 |
| HeadacheNervous system disorders | 21/421 | 35/420 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 30/421 | 24/420 |
| Upper respiratory tract infectionInfections and infestations | 22/421 | 22/420 |
| SinusitisInfections and infestations | 22/421 | 19/420 |
| Age, Categorical(Participants) | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 222 | 204 | 426 |
| >=65 years | 199 | 216 | 415 |
| Age Continuous(years) | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily | Total |
|---|---|---|---|
| Mean | 63.3 ± 9.5 | 64.2 ± 9.3 | 63.8 ± 9.4 |
| Sex/Gender, Customized(participants) | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily | Total |
|---|---|---|---|
| Female | 178 | 183 | 361 |
| Male | 243 | 236 | 479 |
| Undifferentiated | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 9 | 24 |
| Not Hispanic or Latino | 402 | 411 | 813 |
| Unknown or Not Reported | 4 | 0 | 4 |
| Race (NIH/OMB)(Participants) | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 43 | 45 | 88 |
| White | 374 | 372 | 746 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily | Total |
|---|---|---|---|
| United States | 421 | 420 | 841 |
| Number of COPD exacerbations in last year(Number of occurrences) | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily | Total |
|---|---|---|---|
| Mean | 0.8 ± 1.1 | 1.0 ± 1.4 | 0.9 ± 1.3 |
| FEV1(Liter) | Placebo Comparator: Placebo Twice Daily | Experimental: Arformoterol 15 Mcg Twice Daily | Total |
|---|---|---|---|
| Mean | 1.178 ± 0.487 | 1.176 ± 0.482 | 1.177 ± 0.485 |
5 further baseline measures are reported on the registry.
The record gives a start of Jun 2009, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol
Pulmonary Disease, Chronic Obstructive →
Sumitomo Pharma America, Inc. →